Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + irinotecan + fluorouracil + capecitabine
- Development stage
- Phase 2
- Lead developer
- Hôpital Jean Minjoz
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy regimen consisting of the monoclonal antibody bevacizumab and a chemotherapy backbone of irinotecan and fluorouracil (modified FOLFIRI-3), followed by maintenance therapy with bevacizumab and capecitabine. Bevacizumab is a recombinant humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF), thereby inhibiting tumor angiogenesis. Irinotecan is a cytotoxic agent that inhibits DNA topoisomerase I, leading to double-strand DNA breaks. Fluorouracil and its oral prodrug capecitabine are antimetabolites that inhibit thymidylate synthase, disrupting DNA synthesis. This specific sequential regimen was investigated in a Phase II clinical trial (NCT00405379) sponsored by Hôpital Jean Minjoz for the treatment of patients with previously untreated metastatic colorectal adenocarcinoma.
- Other names
- bevacizumab + modified FOLFIRI-3 followed by bevacizumab + capecitabinebevacizumab + FOLFIRI-3
02
Targets
Beyond the preview
Go deeper on bevacizumab + irinotecan + fluorouracil + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + irinotecan + fluorouracil + capecitabine.